Insulet to Preview New Clinical Data & Next Generation Omnipod® System at the American Diabetes Association’s 77th Scienti...
June 09 2017 - 6:00AM
Business Wire
Company Further Demonstrates Significant Impact
on Improving the Quality of Life of People with Diabetes
Insulet Corporation (NASDAQ: PODD) (Insulet or the
Company), the leader in tubeless insulin pump technology with its
Omnipod® Insulin Management System (Omnipod System), today
announced it will present new data for its Omnipod System including
results from a hybrid closed-loop study utilizing the Omnipod
Horizon™ Automated Glucose Control System (Omnipod Horizon System)
involving a total of 24 pediatric patients from six to 18 years of
age at the American Diabetes Association (ADA) 77th Scientific
Sessions at the San Diego Convention Center June 9-13, 2017.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170609005121/en/
“We are deeply committed to delivering product innovation that
provides our Podders with the technology and support they need to
simplify their lives and ease the burden of diabetes,” said Shacey
Petrovic, President and Chief Operating Officer. “With this
compelling clinical data and groundbreaking new technology in
development, we continue to provide our users and their health care
providers with robust and simplified solutions to enhance quality
of life and promote successful diabetes management.”
Insulet will exhibit at this year’s Scientific Session at
Booth Location 507 and have four poster presentations to
share new clinical data supporting the benefits of both its current
Omnipod System, as well as its Omnipod Horizon Automated Glucose
Control System.
Dr. Bruce Buckingham, Professor of Pediatric Endocrinology at
the Lucille Salter Packard Children's Hospital, Stanford
University, and Principal Investigator, will be presenting the
hybrid closed-loop study outcomes.
Omnipod presentations at ADA
include:
Poster Number & Title*
Date / PT
Location
1744-P: Impact of the Omnipod
Insulin Management Systemon Glycemic Control: A Survey of the T1D
Exchange GluOnline Community
Saturday, June 10, 11:30 a.m. – 12:30 p.m.
Poster Hall
132-LB: Safety and Feasibility of
Omnipod Hybrid Closed-Loop in Children Aged 6-12 Years with Type 1
DiabetesUsing a Personalized Model Predictive Control Algorithm
Sunday, June 11, 12:00 p.m. – 1:00 p.m.
Poster Hall
1055-P: Safety and Feasibility of
Omnipod Hybrid Closed-Loop in Adolescents with Type 1 Diabetes
Using aPersonalized Model Predictive Control Algorithm
Sunday, June 11, 12:00 p.m. – 1:00 p.m.
Poster Hall
1423-P: A Quality Improvement
Protocol Using OnlyTubeless Insulin Pumps for Treatment of
HospitalizedChildren and Adolescents with Diabetes Mellitus
Monday, June 12, 12:00 p.m. – 1:00 p.m.
Poster Hall
* Data subject to embargo
until Saturday, June 10, 2017
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD) is an innovative medical
device company dedicated to making the lives of people with
diabetes easier. Through its Omnipod Insulin Management System,
Insulet seeks to expand the use of insulin pump therapy among
people with insulin-dependent diabetes. The Omnipod is a
revolutionary and easy-to-use tubeless insulin pump that provides
up to three days of non-stop insulin delivery, without the need to
see or handle a needle. Insulet's Delivery Systems business also
partners with global pharmaceutical and biotechnology companies to
adapt the Omnipod technology platform for the delivery of
subcutaneous drugs across multiple therapeutic areas. Founded in
2000, Insulet Corporation is based in Billerica, Massachusetts. For
more information, please visit: http://www.myomnipod.com.
Forward-Looking Statement:
This press release may contain forward-looking statements
concerning Insulet's expectations, anticipations,
intentions, beliefs or strategies regarding the future. These
forward-looking statements are based on its current expectations
and beliefs concerning future developments and their potential
effects on Insulet. There can be no assurance that future
developments affecting Insulet will be those that it has
anticipated. These forward-looking statements involve a number of
risks, uncertainties (some of which are beyond its control) or
other assumptions that may cause actual results or performance to
be materially different from those expressed or implied by these
forward-looking statements, and other risks and uncertainties
described in its Annual Report on Form 10-K, which was filed with
the Securities and Exchange Commission on February
28, 2017 in the section entitled "Risk Factors," and in its
other filings from time to time with the Securities and
Exchange Commission. Should one or more of these risks or
uncertainties materialize, or should any of its assumptions prove
incorrect, actual results may vary in material respects from those
projected in these forward-looking
statements. Insulet undertakes no obligation to publicly
update or revise any forward-looking statements.
© 2017 Insulet Corporation, Horizon, Omnipod and Podder are
trademarks or registered trademarks of Insulet Corporation. All
rights reserved. All other trademarks are the property of their
respective owners. The use of third party trademarks does not
constitute an endorsement or imply a relationship or other
affiliation.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170609005121/en/
Insulet CorporationDeborah R. Gordon, 978-600-7717Vice
President, Investor Relations and Corporate
Communicationsdgordon@insulet.com
Insulet (NASDAQ:PODD)
Historical Stock Chart
From Apr 2024 to May 2024
Insulet (NASDAQ:PODD)
Historical Stock Chart
From May 2023 to May 2024